{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:07:26Z","timestamp":1788887246054,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005721","name":"Universit\u00e4t Bielefeld","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Most cancer-related deaths worldwide are associated with lung cancer. Subtyping of non-small cell lung cancer (NSCLC) into adenocarcinoma (AC) and squamous cell carcinoma (SqCC) is of importance, as therapy regimes differ. However, conventional staining and immunohistochemistry have their limitations. Therefore, a spatial metabolomics approach was aimed to detect differences between subtypes and to discriminate tumor and stroma regions in tissues.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fresh-frozen NSCLC tissues (<jats:italic>n<\/jats:italic>\u2009=\u200935) were analyzed by matrix-assisted laser desorption\/ionization-mass spectrometry imaging (MALDI-MSI) of small molecules (&lt;\u2009m\/z\u00a01000). Measured samples were subsequently stained and histopathologically examined. A differentiation of subtypes and a discrimination of tumor and stroma regions was performed by receiver operating characteristic analysis and machine learning algorithms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Histology-guided spatial metabolomics revealed differences between AC and SqCC and between NSCLC tumor and tumor microenvironment. A diagnostic ability of 0.95 was achieved for the discrimination of AC and SqCC. Metabolomic contrast to the tumor microenvironment was revealed with an area under the curve of 0.96 due to differences in phospholipid profile. Furthermore, the detection of NSCLC with rarely arising mutations of the isocitrate dehydrogenase (IDH) gene was demonstrated through 45 times enhanced oncometabolite levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>MALDI-MSI of small molecules can contribute to NSCLC subtyping. Measurements can be performed intraoperatively on a single tissue section to support currently available approaches. Moreover, the technique can be beneficial in screening of <jats:italic>IDH<\/jats:italic>-mutants for the characterization of these seldom cases promoting the development of treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03834-w","type":"journal-article","created":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T09:02:21Z","timestamp":1638090141000},"page":"351-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Subtyping non-small cell lung cancer by histology-guided spatial metabolomics"],"prefix":"10.1007","volume":"148","author":[{"given":"Judith Martha","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin Saskia","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Niehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8307-7246","authenticated-orcid":false,"given":"Hanna","family":"Bednarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,28]]},"reference":[{"key":"3834_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/labinvest.2014.156","volume":"95","author":"M Aichler","year":"2015","unstructured":"Aichler M, Walch A (2015) MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Investig 95:422\u2013431. https:\/\/doi.org\/10.1038\/labinvest.2014.156","journal-title":"Lab Investig"},{"key":"3834_CR2","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"3834_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41698-019-0089-y","volume":"3","author":"SS Basu","year":"2019","unstructured":"Basu SS, Regan MS, Randall EC, Abdelmoula WM, Clark AR, Gimenez-Cassina Lopez B, Cornett DS, Haase A, Santagata S, Agar NYR (2019) Rapid MALDI mass spectrometry imaging for surgical pathology. NPJ Precis Oncol 3:17. https:\/\/doi.org\/10.1038\/s41698-019-0089-y","journal-title":"NPJ Precis Oncol"},{"key":"3834_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2020.101055","volume":"80","author":"KC Corn","year":"2020","unstructured":"Corn KC, Windham MA, Rafat M (2020) Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res 80:101055. https:\/\/doi.org\/10.1016\/j.plipres.2020.101055","journal-title":"Prog Lipid Res"},{"key":"3834_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739\u2013744. https:\/\/doi.org\/10.1038\/nature08617","journal-title":"Nature"},{"key":"3834_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fonc.2019.00417","volume":"9","author":"D Golub","year":"2019","unstructured":"Golub D, Iyengar N, Dogra S, Wong T, Bready D, Tang K, Modrek AS, Placantonakis DG (2019) Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol 9:417. https:\/\/doi.org\/10.3389\/fonc.2019.00417","journal-title":"Front Oncol"},{"key":"3834_CR7","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1038\/srep05959","volume":"4","author":"S Guo","year":"2014","unstructured":"Guo S, Wang Y, Zhou D, Li Z (2014) Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci Rep 4:5959. https:\/\/doi.org\/10.1038\/srep05959","journal-title":"Sci Rep"},{"key":"3834_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13014-018-0982-5","volume":"13","author":"J-M Hu","year":"2018","unstructured":"Hu J-M, Sun H-T (2018) Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation. Radiat Oncol 13:40. https:\/\/doi.org\/10.1186\/s13014-018-0982-5","journal-title":"Radiat Oncol"},{"key":"3834_CR9","doi-asserted-by":"publisher","first-page":"8303","DOI":"10.1021\/ac501937d","volume":"86","author":"EE Jones","year":"2014","unstructured":"Jones EE, Dworski S, Canals D, Casas J, Fabrias G, Schoenling D, Levade T, Denlinger C, Hannun YA, Medin JA, Drake RR (2014) On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging. Anal Chem 86:8303\u20138311. https:\/\/doi.org\/10.1021\/ac501937d","journal-title":"Anal Chem"},{"key":"3834_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2011.10.016","volume":"76","author":"GK Lee","year":"2012","unstructured":"Lee GK, Lee HS, Park YS, Lee JH, Lee SC, Lee JH, Lee SJ, Shanta SR, Park HM, Kim HR, Kim IH, Kim YH, Zo JI, Kim KP, Kim HK (2012) Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. Lung Cancer 76:197\u2013203. https:\/\/doi.org\/10.1016\/j.lungcan.2011.10.016","journal-title":"Lung Cancer"},{"key":"3834_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.semcdb.2019.06.004","volume":"98","author":"B Majem","year":"2020","unstructured":"Majem B, Nadal E, Mu\u00f1oz-Pinedo C (2020) Exploiting metabolic vulnerabilities of non small cell lung carcinoma. Semin Cell Dev Biol 98:54\u201362. https:\/\/doi.org\/10.1016\/j.semcdb.2019.06.004","journal-title":"Semin Cell Dev Biol"},{"key":"3834_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/ijc.29517","volume":"137","author":"E Marien","year":"2015","unstructured":"Marien E, Meister M, Muley T, Fieuws S, Bordel S, Derua R, Spraggins J, van de Plas R, Dehairs J, Wouters J, Bagadi M, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Waelkens E, Swinnen JV (2015) Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles. Int J Cancer 137:1539\u20131548. https:\/\/doi.org\/10.1002\/ijc.29517","journal-title":"Int J Cancer"},{"key":"3834_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/PAS.0b013e3182036d05","volume":"35","author":"S Mukhopadhyay","year":"2011","unstructured":"Mukhopadhyay S, Katzenstein A-LA (2011) Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5\/6. Am J Surg Pathol 35:15\u201325. https:\/\/doi.org\/10.1097\/PAS.0b013e3182036d05","journal-title":"Am J Surg Pathol"},{"key":"3834_CR14","doi-asserted-by":"publisher","first-page":"8916","DOI":"10.1038\/s41598-019-45506-3","volume":"9","author":"Y Muranishi","year":"2019","unstructured":"Muranishi Y, Sato T, Ito S, Satoh J, Yoshizawa A, Tamari S, Ueda Y, Yutaka Y, Menju T, Nakamura T, Date H (2019) The ratios of monounsaturated to saturated phosphatidylcholines in lung adenocarcinoma microenvironment analyzed by liquid chromatography-mass spectrometry and imaging mass spectrometry. Sci Rep 9:8916. https:\/\/doi.org\/10.1038\/s41598-019-45506-3","journal-title":"Sci Rep"},{"key":"3834_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","volume":"52","author":"L Osmani","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103\u2013109. https:\/\/doi.org\/10.1016\/j.semcancer.2017.11.019","journal-title":"Semin Cancer Biol"},{"key":"3834_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006","journal-title":"Cell Metab"},{"key":"3834_CR17","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.humpath.2012.05.003","volume":"43","author":"D Rakheja","year":"2012","unstructured":"Rakheja D, Konoplev S, Medeiros LJ, Chen W (2012) IDH mutations in acute myeloid leukemia. Hum Pathol 43:1541\u20131551. https:\/\/doi.org\/10.1016\/j.humpath.2012.05.003","journal-title":"Hum Pathol"},{"key":"3834_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/carcin\/bgu226","volume":"36","author":"CM Rocha","year":"2015","unstructured":"Rocha CM, Barros AS, Goodfellow BJ, Carreira IM, Gomes A, Sousa V, Bernardo J, Carvalho L, Gil AM, Duarte IF (2015) NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis 36:68\u201375. https:\/\/doi.org\/10.1093\/carcin\/bgu226","journal-title":"Carcinogenesis"},{"key":"3834_CR19","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1002\/cam4.3058","volume":"9","author":"EF Rodriguez","year":"2020","unstructured":"Rodriguez EF, de Marchi F, Lokhandwala PM, Belchis D, Xian R, Gocke CD, Eshleman JR, Illei P, Li M-T (2020) IDH1 and IDH2 mutations in lung adenocarcinomas: evidences of subclonal evolution. Cancer Med 9:4386\u20134394. https:\/\/doi.org\/10.1002\/cam4.3058","journal-title":"Cancer Med"},{"key":"3834_CR20","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomark Prev 28:1563\u20131579. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0221","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3834_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2016.11.001","volume":"134","author":"K Schwamborn","year":"2017","unstructured":"Schwamborn K (2017) The importance of histology and pathology in mass spectrometry imaging. Adv Cancer Res 134:1\u201326. https:\/\/doi.org\/10.1016\/bs.acr.2016.11.001","journal-title":"Adv Cancer Res"},{"key":"3834_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.molonc.2010.09.002","volume":"4","author":"K Schwamborn","year":"2010","unstructured":"Schwamborn K, Caprioli RM (2010) MALDI imaging mass spectrometry\u2014painting molecular pictures. Mol Oncol 4:529\u2013538. https:\/\/doi.org\/10.1016\/j.molonc.2010.09.002","journal-title":"Mol Oncol"},{"key":"3834_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-019-0464-z","volume":"121","author":"K Sellers","year":"2019","unstructured":"Sellers K, Allen TD, Bousamra M, Tan J, M\u00e9ndez-Lucas A, Lin W, Bah N, Chernyavskaya Y, MacRae JI, Higashi RM, Lane AN, Fan TW-M, Yuneva MO (2019) Metabolic reprogramming and notch activity distinguish between non-small cell lung cancer subtypes. Br J Cancer 121:51\u201364. https:\/\/doi.org\/10.1038\/s41416-019-0464-z","journal-title":"Br J Cancer"},{"key":"3834_CR24","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/annonc\/mdr489","volume":"22","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616\u20132624. https:\/\/doi.org\/10.1093\/annonc\/mdr489","journal-title":"Ann Oncol"},{"key":"3834_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/01.ftd.0000179845.53213.39","volume":"27","author":"CA Smith","year":"2005","unstructured":"Smith CA, O\u2019Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, Abagyan R, Siuzdak G (2005) METLIN: a metabolite mass spectral database. Ther Drug Monit 27:747\u2013751. https:\/\/doi.org\/10.1097\/01.ftd.0000179845.53213.39","journal-title":"Ther Drug Monit"},{"key":"3834_CR26","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3834_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.humpath.2018.04.014","volume":"78","author":"LN Toth","year":"2018","unstructured":"Toth LN, de Abreu FB, Tafe LJ (2018) Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1\/2) mutations. Hum Pathol 78:138\u2013143. https:\/\/doi.org\/10.1016\/j.humpath.2018.04.014","journal-title":"Hum Pathol"},{"key":"3834_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00432-019-03079-8","volume":"146","author":"B-Y Wang","year":"2020","unstructured":"Wang B-Y, Huang J-Y, Chen H-C, Lin C-H, Lin S-H, Hung W-H, Cheng Y-F (2020) The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol 146:43\u201352. https:\/\/doi.org\/10.1007\/s00432-019-03079-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"3834_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765\u2013773. https:\/\/doi.org\/10.1056\/NEJMoa0808710","journal-title":"N Engl J Med"},{"key":"3834_CR30","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.180086","author":"B Yan","year":"2018","unstructured":"Yan B, Hu Y, Ma T, Wang Y (2018) IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5. Open Biol. https:\/\/doi.org\/10.1098\/rsob.180086","journal-title":"Open Biol"},{"key":"3834_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3389\/fonc.2019.00804","volume":"9","author":"M Zhang","year":"2019","unstructured":"Zhang M, He J, Li T, Hu H, Li X, Xing H, Wang J, Yang F, Ma Q, Liu B, Tang C, Abliz Z, Liu X (2019) Accurate classification of non-small cell lung cancer (NSCLC) pathology and mapping of EGFR mutation spatial distribution by ambient mass spectrometry imaging. Front Oncol 9:804. https:\/\/doi.org\/10.3389\/fonc.2019.00804","journal-title":"Front Oncol"},{"key":"3834_CR32","doi-asserted-by":"publisher","first-page":"57680","DOI":"10.18632\/oncotarget.17016","volume":"8","author":"Q-G Zhu","year":"2017","unstructured":"Zhu Q-G, Zhang S-M, Ding X-X, He B, Zhang H-Q (2017) Driver genes in non-small cell lung cancer: characteristics, detection methods, and targeted therapies. Oncotarget 8:57680\u201357692. https:\/\/doi.org\/10.18632\/oncotarget.17016","journal-title":"Oncotarget"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03834-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:05:07Z","timestamp":1643483107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03834-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,28]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3834"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03834-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,28]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Klinisches Ethikkomitee des HDZ NRW (AZ-2019-565).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All individual patients gave informed consent about usage of resected material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}